Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-23-038526
Filing Date
2023-02-14
Accepted
2023-02-14 13:34:02
Documents
3
Group Members
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUSTMACQUARIE MANAGEMENT HOLDINGS INC

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d403453dsc13ga.htm SC 13G/A 74906
2 EX-99.A d403453dex99a.htm EX-99.A 20300
3 EX-99.B d403453dex99b.htm EX-99.B 993
  Complete submission text file 0001193125-23-038526.txt   97805
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Subject) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-82196 | Film No.: 23626513
SIC: 2834 Pharmaceutical Preparations

Mailing Address 50 MARTIN PLACE SYDNEY, NSW 2000 C3 2000
Business Address 50 MARTIN PLACE SYDNEY, NSW 2000 C3 2000 212.231.1000
MACQUARIE GROUP LTD (Filed by) CIK: 0001418333 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: SC 13G/A